Search
Search Results
-
SIRT1 mediates breast cancer development and tumorigenesis controlled by estrogen-related receptor β
Silent mating type information regulation 2 homolog 1 (SIRT1) is a class III histone deacetylase (HDAC) that is NAD + dependent and essential for...
-
Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021
The United States Food and Drug Administration (US FDA) has always been a forerunner in drug evaluation and supervision. Over the past 31 years, 1050...
-
Recent advances in targeted strategies for triple-negative breast cancer
Triple-negative breast cancer (TNBC), a highly aggressive subtype of breast cancer, negatively expresses estrogen receptor, progesterone receptor,...
-
Selective targeting of the androgen receptor-DNA binding domain by the novel antiandrogen SBF-1 and inhibition of the growth of prostate cancer cells
Prostate cancers are reliant on androgens for growth and survival. Clinicians and researchers are looking for potent treatments for the resistant...
-
Advances in Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer
Purpose of ReviewTo provide an overview of the current management of hormone receptor-positive (HR +) advanced breast cancer as well as highlight...
-
Cardiovascular Toxicity of Androgen Deprivation Therapy
Purpose of ReviewAndrogen deprivation therapy (ADT) is the standard of care for the treatment of advanced prostate cancer (PC). ADT, particularly...
-
Impact of disease volume on survival efficacy of triplet therapy for metastatic hormone-sensitive prostate cancer: a systematic review, meta-analysis, and network meta-analysis
BackgroundTriplet therapy, androgen receptor signaling inhibitors (ARSIs) plus docetaxel plus androgen-deprivation therapy (ADT), is a novel...
-
Targeting a splicing-mediated drug resistance mechanism in prostate cancer by inhibiting transcriptional regulation by PKCβ1
The androgen receptor (AR) is a central driver of aggressive prostate cancer. After initial treatment with androgen receptor signaling inhibitors...
-
Evidence-based capacity of natural cytochrome enzyme inhibitors to increase the effectivity of antineoplastic drugs
AbstractCytochrome (CYP) enzymes catalyze the metabolism of numerous exogenous and endogenous substrates in cancer therapy leading to significant...
-
Cancer-biomarkers associated with sex hormone receptors and recent therapeutic advancements: a comprehensive review
Hormones and its regulation plays vital role in causing breast, prostate, ovarian and endometrial cancers collectively known as hormone-sensitive...
-
Bile acid metabolism and signaling in health and disease: molecular mechanisms and therapeutic targets
Bile acids, once considered mere dietary surfactants, now emerge as critical modulators of macronutrient (lipid, carbohydrate, protein) metabolism...
-
Long-lasting complete remission in a patient with systemic metastases of recurrent breast cancer treated with cyclin-dependent kinases 4/6 inhibitors: a case report
BackgroundThe prognosis for recurrence cases of hormone receptor-positive HER2-negative breast cancer remains poor, and treatment strategies that...
-
Disruption of androgen signaling during puberty affects Notch pathway in rat seminiferous epithelium
BackgroundOnset of spermatogenesis at puberty is critically dependent on the activity of hypothalamic-pituitary-gonadal axis and testosterone...
-
Histone methyltransferase SUV39H2 regulates apoptosis and chemosensitivity in prostate cancer through AKT/FOXO signaling pathway
Prostate cancer (PCa) is one of the most common malignant tumors that exhibit both chemoresistance and recurrence. SUV39H2 is highly expressed in...
-
Targeting PELP1 oncogenic signaling in TNBC with the small molecule inhibitor SMIP34
PurposeTriple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer. Oncogenic PELP1 is frequently overexpressed in TNBC, and...
-
Applications and clinical trial landscape using Toll-like receptor agonists to reduce the toll of cancer
Toll-like receptors (TLRs), which serve as a bridge between innate and adaptive immunity, may be viable treatment targets. TLRs are the first line of...
-
Cardiovascular Toxicities of Androgen Deprivation Therapy
Prostate cancer is the second leading cause of cancer death in men, and cardiovascular disease is the number one cause of death in patients with...
-
Sodium-glucose cotransporter 2 inhibitors and cancer: a systematic review and meta-analysis
BackgroundThe effect of sodium–glucose cotransporter 2 (SGLT2) inhibitors on cancer has yet to be fully elucidated.
ObjectiveThis systematic review...
-
Enzalutamide: Understanding and Managing Drug Interactions to Improve Patient Safety and Drug Efficacy
Enzalutamide is an oral androgen receptor signaling inhibitor utilized in the treatment of men with prostate cancer. It is a moderate inducer of the...
-
Castration immunoregulates toll-like receptor-4 in male bladder cancer
PurposeAmong diverse Pattern Recognition Receptors (PRRs), Toll-like receptor-4 (TLR-4) is a key urothelial trigger for innate immune response...
